Previous 10 | Next 10 |
Can-Fite BioPharma (NYSE:CANF) ADRs have surged ~16.6% in the pre-market after the company announced that it was filing new patent applications in several countries for the treatment of all advanced solid tumors following the Phase 2 data for its liver drug Namodenoson. The decision...
Namodenoson Headed into Pivotal Phase III Liver Cancer Study Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today anno...
Gainers: Reliance Global Group (NASDAQ:RELI) +89%. Biofrontera (NASDAQ:BFRI) +49%. IsoPlexis Corporation (NASDAQ:ISO) +37%. Chemomab Therapeutics (NASDAQ:CMMB) +29%. iSpecimen (NASDAQ:ISPC) +28%. Aldeyra Therapeutics (NASDAQ:ALDX) -51%. DBV Technologies...
Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...
Body: Can-Fite BioPharma (NYSE:CANF) announces the agreement by an institutional investor to exercise certain warrants to purchase up to an aggregate of 150M shares represented by 5M ADSs having an exercise price of $2.00/ADS at an exercise price of $2.00 per ADSs for gross proceeds of $10M. ...
PETACH TIKVA, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the agreement by an healt...
Gainers: Society Pass (NASDAQ:SOPA) +237%. Bluerock Residential Growth (NYSE:BRG) +71%. Can-Fite (NYSE:CANF) +59%. AeroClean (NASDAQ:AERC) +58%. Galera Therapeutics (NASDAQ:GRTX) +38%. Verso (NYSE:VRS) +35%. Roivant (NASDAQ:ROIV) +26%. Venus (NASDAQ:VERO) +25%. BioCardia (NASDAQ:BCDA) +1...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rocket Companies (NYSE: RKT ) stock is on the move Monday following news of an acquisition deal with Truebill. Source: Lori Butcher / Shutterstock.com Let’s break down that deal below for potential RK...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Can-Fite BioPharma (NYSEAMERICAN: CANF ) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial. Source: Shutterstock The big news today comes from the last person signed up to t...
Can-Fite BioPharma (NYSE:CANF) soars 87.4% premarket after announcing that the last patient treated under an Open Label Extension program of its concluded Phase II study of Namodenoson in the treatment of hepatocellular carcinoma (HCC), experienced a Complete Response (CR), meaning ...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...